Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
113.57
-4.96 (-4.18%)
Mar 31, 2025, 9:43 AM EDT - Market open
Axsome Therapeutics Revenue
In the year 2024, Axsome Therapeutics had annual revenue of $385.69M with 42.53% growth. Axsome Therapeutics had revenue of $118.77M in the quarter ending December 31, 2024, with 66.04% growth.
Revenue (ttm)
$385.69M
Revenue Growth
+42.53%
P/S Ratio
14.72
Revenue / Employee
$564,704
Employees
683
Market Cap
5.54B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
AXSM News
- 6 days ago - Axsome Therapeutics' ADHD drug meets main goal in late-stage study - Reuters
- 9 days ago - Axsome: The Alzheimer's Agitation Program For AXS-05 - Seeking Alpha
- 4 weeks ago - Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs - Benzinga
- 5 weeks ago - Axsome Q4 Earnings: Revenues Rising, Skepticism Lingering - Seeking Alpha
- 5 weeks ago - Axsome Therapeutics, Inc. (AXSM) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade - Seeking Alpha
- 6 weeks ago - Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025' - Benzinga
- 2 months ago - Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader - GlobeNewsWire